MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326783 | Name: Manidipine HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Manidipine, also known as CV-4093, is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. In addition, manidipine does not significantly affect norepinephrine levels, suggesting a lack of sympathetic activation. Manidipine has shown antihypertensive efficacy and appears to be well tolerated in adult and elderly patients with mild or moderate essential hypertension.

Chemical Structure

Manidipine HCl
Manidipine HCl
CAS#89226-75-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 326783

Name: Manidipine HCl

CAS#: 89226-75-5 (HCl)

Chemical Formula: C35H40Cl2N4O6

Exact Mass: 0.0000

Molecular Weight: 683.63

Elemental Analysis: C, 61.49; H, 5.90; Cl, 10.37; N, 8.20; O, 14.04

Price and Availability

Size Price Availability Quantity
200mg USD 150.00 2 Weeks
500mg USD 250.00 2 Weeks
1g USD 400.00 2 Weeks
2g USD 650.00 2 Weeks
5g USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
89226-75-5 (HCl) 89226-50-6 (free base)
Synonym
CV-4093; CV 4093; CV4093; Manidipine HCl
IUPAC/Chemical Name
3-(2-(4-benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride
InChi Key
JINNGBXKBDUGQT-UHFFFAOYSA-N
InChi Code
InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#89226-75-5 (Manidipine HCl); CAS#89226-50-6 (Manidipine free base).

Preparing Stock Solutions

The following data is based on the product molecular weight 683.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs. 2001;61(12):1777-99. doi: 10.2165/00003495-200161120-00010. PMID: 11693466. 2: SaizSatjes M, Martinez-Martin FJ. Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes. Drugs Context. 2018 Jan 3;7:212509. doi: 10.7573/dic.212509. PMID: 29344052; PMCID: PMC5764490. 3: McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923-40. doi: 10.2165/00003495-200464170-00011. PMID: 15329044. 4: McCormack PL, Keating GM. Delapril/manidipine. Drugs. 2006;66(7):961-9. doi: 10.2165/00003495-200666070-00014. PMID: 16740017. 5: Roca-Cusachs A, Triposkiadis F. Antihypertensive effect of manidipine. Drugs. 2005;65 Suppl 2:11-9. doi: 10.2165/00003495-200565002-00003. PMID: 16398058. 6: Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs. 2009;9(3):163-76. doi: 10.1007/BF03256573. PMID: 19463022. 7: Buset Ríos N, Rodríguez Esparragón F, Fernández-Andrade Rodríguez C, Rodríguez Pérez JC. Vascular and metabolic properties of manidipine. Nefrologia. 2011;31(3):268-74. English, Spanish. doi: 10.3265/Nefrologia.pre2010.Nov.10643. Epub 2011 Mar 15. PMID: 21407275. 8: Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig. 2011;31(7):439-53. doi: 10.2165/11589000-000000000-00000. PMID: 21627336. 9: Otero ML. Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag. 2007;3(3):255-63. PMID: 17703633; PMCID: PMC2293964. 10: Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Rev Cardiovasc Ther. 2007 Mar;5(2):147-59. doi: 10.1586/14779072.5.2.147. PMID: 17338661. 11: Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):751-7. doi: 10.1586/erc.10.48. PMID: 20528630. 12: Kahan T, Ambrosioni E. Delapril/manidipine: viewpoints. Drugs. 2006;66(7):970-1. doi: 10.2165/00003495-200666070-00016. PMID: 16740019. 13: Saiz Satjes M, Martinez-Martin FJ. Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine. Future Cardiol. 2016 Jul;12(4):435-47. doi: 10.2217/fca-2016-0027. Epub 2016 May 25. PMID: 27221471. 14: Zhang R, Zhou J, Yan H, Liu X, Shang C, Chen Y. Manidipine is not a potential inhibitor against SARS-CoV-2 main protease. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0129723. doi: 10.1128/aac.01297-23. Epub 2024 Jan 31. PMID: 38294235; PMCID: PMC10916385. 15: Rodicio JL. Renal effects of calcium antagonists with special reference to manidipine hydrochloride. Blood Press Suppl. 1996;5:10-5. PMID: 8973787. 16: Lee H, Kim JW, Lee DS, Min SH. Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness. Int J Mol Sci. 2020 Oct 6;21(19):7379. doi: 10.3390/ijms21197379. PMID: 33036254; PMCID: PMC7583017. 17: Costa S, Zimetti F, Pedrelli M, Cremonesi G, Bernini F. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res. 2010 Sep;62(3):265-70. doi: 10.1016/j.phrs.2010.03.004. Epub 2010 Mar 27. PMID: 20347984. 18: Nagaoka A. Pharmacologic characteristics of a new calcium antagonist, manidipine: beneficial effects on renal circulation and vascular changes. Am Heart J. 1993 Feb;125(2 Pt 2):560-5. doi: 10.1016/0002-8703(93)90203-l. PMID: 8430600. 19: Huang S, Simonson MS, Dunn MJ. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J. 1993 Feb;125(2 Pt 2):589-97. doi: 10.1016/0002-8703(93)90208-q. PMID: 8381576. 20: Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, Rodriguez-Rosas H, Soriano-Perera P, Pedrianes-Martin P. Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Clin Drug Investig. 2011;31(3):201-12. doi: 10.2165/11587590-000000000-00000. PMID: 21155616.